BHST

BioHarvest Sciences Inc. (BHST) 10Y Growth Potential Analysis (2026)

Invetso Score: 4.3/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 4.6 (Moderate)

Revenue growth evidence is limited by missing five-year CAGR data, so long-term expansion must be inferred from current spending intensity rather than proven compounding.

R&D at 16.3% of revenue suggests continued product investment, but peers with demonstrated revenue CAGR offer stronger proof of scalable monetization.

Low capex at 6.3% of revenue supports asset-light growth, yet negative ROIC indicates reinvestment has not translated into superior revenue expansion versus peers.

Negative net debt implies balance-sheet flexibility for future growth funding, but current operating returns remain weaker than peers with proven self-funded scaling.

Market Tailwinds

Score:

No direct market-share or segment-concentration data is provided, limiting evidence that BHST benefits from stronger structural demand than direct peers.

The company’s growth case appears more dependent on internal execution than on visible multi-year tailwinds, unlike peers with documented category expansion.

Missing HHI and largest-share metrics prevent confirmation of durable share gains, which weakens confidence in long-term revenue compounding versus competitors.

Current metrics show no clear proof of accelerating end-market demand, so peer-relative tailwinds remain unsubstantiated rather than structurally strong.

Scalability Expansion

Score:

Asset-light capex intensity can support scaling, but negative ROIC suggests incremental growth has not yet produced efficient expansion versus peers.

Cash conversion cycle of 119 days indicates working-capital drag, which can slow reinvestment velocity relative to more efficient competitors.

Negative interest coverage and weak operating returns constrain financial flexibility, reducing the company’s ability to compound revenue faster than stronger peers.

The absence of historical growth metrics makes scalable expansion harder to verify, leaving BHST below peers with demonstrated multi-year operating leverage.

Constraints Limitations

Score:

Negative ROIC is the clearest structural constraint, because it implies new capital has not been converted into durable revenue growth efficiently.

A long cash conversion cycle ties up capital in operations, limiting reinvestment speed versus peers with faster working-capital turnover.

Negative interest coverage signals limited earnings support for expansion, which can constrain growth funding relative to better-capitalized competitors.

Missing five-year growth and segmentation data create visibility gaps, but the more important issue is weak evidence of scalable monetization.

Overall Score

Score:

BHST shows some growth capacity from low capex and balance-sheet flexibility, but weak returns and poor working-capital efficiency limit peer-relative compounding potential.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on BioHarvest Sciences Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →